<DOC>
	<DOC>NCT00658086</DOC>
	<brief_summary>To evaluate the safety,tolerability and antiviral activitity of ALN-RSV01 in RSV infected lung transplant patients</brief_summary>
	<brief_title>Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>Single or bilateral lung transplant recipients Confirmed RSV infection Greater than 90 days post current lung transplant Rejection free for a minimum of 1 month Antimicrobial therapy for known viral, bacterial, or fungal respiratory coinfection at the time of diagnosis Bronchiolitis obliterans syndrome (BOS) Grade 3 or any state BOS with FEV1 that has not been stable for at least 3 months Use of alemtuzumab within 9 months prior to screening; antithymocyte globulin(ATG) or thymoglobulin within 3 months of screening: concurrent use of &gt;= 0.3 mg/kg/day prednisone or equivalent as maintenance therapy active treament for acute graft rejection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>ALN-RSV01</keyword>
	<keyword>Respiratory Syncytial Virus</keyword>
</DOC>